Evommune Enters Exclusive License Agreement with Hinova for EVO570, an Oral VAV1 Molecular Glue Degrader

Shots: Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals for worldwide rights (ex-Greater China) to develop, manufacture & commercialize EVO570 (formerly HC118/HP570), an oral VAV1-directed molecular glue degrader Evommune will pay $30M upfront ($20M cash + $10M in pre-funded warrants); Hinova is eligible for up to ~$1.1B in development, regulatory & commercial milestones, plus tiered royalties on net sales outside Greater China EVO570 IND applications have been submitted in China & accepted in the US; a P-I trial assessing safety, PK & target engagement is expected to begin imminently, with a P-II in rheumatoid arthritis planned for 2027 Ref: Evommune  |   Image: Evommune & Hinova  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Evommune Enters Exclusive License Agreement with Hinova for EVO570, an Oral VAV1 Molecular Glue Degrader appeared first on PharmaShots.